Soleno Therapeutics, Inc. (NASDAQ:SLNO) is awaited to publish earnings on April, 1., as reported by RTT. Analysts predict $-0.28 EPS, which is $0.11 up or 28.21 % from 2018’s $-0.39 EPS. Last quarter $-0.11 EPS was reported. Analysts sees 154.55 % negative EPS growth this quarter. Ticker’s shares touched $1.51 during the last trading session after 2.72% change.Soleno Therapeutics, Inc. has volume of 5,154 shares. Since March 12, 2018 SLNO has declined 12.28% and is downtrending. The stock underperformed the S&P 500 by 16.65%.

Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.The firm is worth $47.95 million. The company's lead candidate, diazoxide choline controlled-release , a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into Phase II/III clinical development.Last it reported negative earnings. It also markets medical devices, including the CoSense End-Tidal Carbon Monoxide (ETCO) monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns; and NeoPip T-piece resuscitator and related consumables, which deliver consistent pre-set inspiratory pressure and positive end-expiratory pressures, as well as temperature probes, scales, surgical tables, and patient surfaces.

For more Soleno Therapeutics, Inc. (NASDAQ:SLNO) news published recently go to: Globenewswire.com, Globenewswire.com, Seekingalpha.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Low Lean Body Mass in Prader-Willi Syndrome – GlobeNewswire” published on September 04, 2018, “Soleno Therapeutics Presents Clinical Data on DCCR at Late-Breaking Session of European Society for Paediatric Endocrinology – GlobeNewswire” on October 01, 2018, “Soleno Therapeutics secures $16.5M capital raise – Seeking Alpha” with a publish date: December 19, 2018, “An In-Depth Look At Soleno Therapeutics – Seeking Alpha” and the last “Capnia and Essentialis Announce Merger to Create Rare Disease Therapeutics Company – GlobeNewswire” with publication date: December 27, 2016.